Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker.
Merck & Co., Inc. said on 1 November that it is partnering with Synthekine Inc. to leverage the latter firm’s proprietary surrogate cytokine agonist platform in the discovery, development and commercialization of novel cytokine therapeutics
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?